Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 10/20 | 0.43 |
| ▸ | DRD4 | P21917 | 10/20 | 0.43 |
| ▸ | DRD3 | P35462 | 10/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616500 | 0.94 | DRD2 (0.49) | NOTUMCXCR1DRD2DRD4DRD3 | |
| SCHEMBL13616468 | 0.91 | NOTUM (0.48) | NOTUMCXCR1DRD2DRD4DRD3 | |
| SCHEMBL13616564 | 0.90 | DRD2 (0.44) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL13616569 | 0.83 | DRD2 (0.50) | DRD2DRD4DRD3 | |
| SCHEMBL13616497 | 0.82 | DRD2 (0.62) | DRD2DRD4DRD3 | |
| SCHEMBL4317470 | 0.81 | NOTUM (0.56) | NOTUMCXCR1DRD2DRD4DRD3 | |
| SCHEMBL13616475 | 0.81 | HDAC3 (0.43) | POLBMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL13616471 | 0.80 | DRD2 (0.46) | CXCR1DRD2DRD4DRD3MAPT | |
| SCHEMBL13616467 | 0.79 | SMN1; SMN2 (0.47) | NOTUMDRD2DRD4DRD3POLB | |
| SCHEMBL13616469 | 0.79 | NOTUM (0.51) | NOTUMCXCR1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275594-A1 | 3-HYDRAZONE PIPERAZINYL RIFAMYCIN DERIVATIVES USEFUL AS ANTIMICROBIAL AGENTS | RIF1, ABCC1, HDAC6 | NOTUM 4303/4885CXCR1 3625/4885DRD2 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.